Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: shasta23 who wrote (17892)	3/26/1998 12:10:00 AM
From: bob zagorin	Respond to of 32384

bop increased very slightly today on low volume so, again, not as meaningful. the "moneystream" indicator, which is worden's short term momentum indicator, turned down some. i concur with what others have said...for the time being, we seem to have run out of new buyers..but the NDA could change that.

To: shasta23 who wrote (17892)	3/26/1998 1:41:00 AM
From: Jongmans	Respond to of 32384

Big movers in last session (all up): AFFX,AMGN,ARIA,ARQL,GNE,INCY,NXCO,INHL,SNAP,ILXO etc.. Institutions building positions for the next quarter? We know the results three months from now! Martin

To: shasta23 who wrote (17892)	3/26/1998 6:22:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Here's more news of interest: Wednesday March 25 6:36 PM EST Dual Therapy Effective For Diabetes NEW YORK (Reuters) -- Troglitazone, a new oral diabetes drug, can be effectively combined with insulin or with metformin, another oral diabetes drug, according to two reports published in the March 26th issue of The New England Journal of Medicine. In the first paper, Dr. Sherwyn Schwartz, of the Diabetes and Glandular Diseases Clinic in San Antonio, Texas, and colleagues report that troglitazone improved the control of type 2 diabetes, the form of the disease that occurs in adults, when it was given daily with at least 30 units of insulin. Over a 26-week treatment period, 116 patients who took 200 mg of troglitazone and 116 patients who took 600 mg of the drug had more significant decreases in glucose values than 118 patients who took insulin plus a placebo -- an inactive pill. Patients who took troglitazone were also able to reduce their dose of insulin. "Troglitazone was well tolerated," Schwartz's team reports, "and most adverse events were considered to be related to the underlying diabetes." "The combined therapy was logical and reversed two abnormalities that patients with this disorder experience," said co-author Dr. Gerald I. Shulman, a Yale professor of medicine, in a statement issued by the university. "Metformin acted primarily to decrease the patients' liver glucose production, while troglitazone worked primarily to enhance the ability of patients' muscle to respond to insulin and take up glucose." "The future of treatment in our type 2 diabetic patients will likely be combination therapy since no single agent will reverse all of the abnormalities seen in our diabetic patients," added Shulman, who is also in investigator with the Howard Hughes Medical Institute at Yale. In the second study, Dr. Silvio Inzucchi of Yale University in New Haven, Connecticut, and others randomly assigned 29 patients with type 2 diabetes to take either troglitazone or metformin for 3 months. The patients then took both drugs for another 3 months. Inzucchi's group found that the two drugs were nearly equally effective at lowering glucose, and combination therapy resulted in further improvement. "Combination therapy is logical for patients with noninsulin-dependent (type 2) diabetes mellitus," the researchers explain, "because they often have poor responses to single-drug therapy." Troglitazone has been associated with liver injury in a small percentage of cases, according to a letter in the same issue of the journal. Dr. Paul B. Watkins, of the University of Michigan, and Dr. Randall W. Whitcomb, of Parke-Davis Pharmaceutical Research, both in Ann Arbor, Michigan, warn that patients receiving this drug should have regular blood tests to detect for liver abnormalities. Troglitazone "is useful either alone or in combination with other drugs for glycemic control in patients with type 2 diabetes," Dr. Hiroo Imura of Kyoto University, Japan, concludes in an accompanying editorial. However, Imura cautions that therapy "...should be limited to patients who can be evaluated frequently until the incidence and severity of (liver) dysfunction with this drug become clearer." According to the American Diabetes Association, about 15 million Americans have diabetes, but over half (8 million) are believed to be undiagnosed. Type 2 diabetes, also known as "adult onset" diabetes, is the most common type of diabetes, and is a leading cause of blindness, kidney failure, and amputation. The disease is the fourth leading cause of death in the US. SOURCE: The New England Journal of Medicine (1998;338:861-866, 867-872, 908-909, 916-917)

To: shasta23 who wrote (17892)	3/26/1998 8:51:00 PM
From: John O'Neill	Read Replies (2) \| Respond to of 32384

stefan.......regarding "fresh blood" I bt back in today at $15. I had sold out earlier & missed my LGND stock. I need to buy 2000 more shares to establish my previous position (sold at ~$16) What's the TA consensus? It broke & closed under 15 1/4 but bounced back from 14 3/4.. It looks like 14 3/4 could be a resistance level.....Whats in between a "flying platform" and regular correction? I sincerely believe that LGND will be stronger for advance over $18 with this type of correction (to as low as around $14, if it goes that low) JO PS tonyt..I'll be listening